The role of vaspin in the development of metabolic and glucose tolerance disorders and atherosclerosis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Dimova, Rumyana ^a   Tankova, Tsvetalina ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

VASPIN; ADIPOCYTOKINE; METFORMIN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN; VASPIN PROTEIN, MOUSE;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DISEASE COURSE; GLUCOSE INTOLERANCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN BLOOD LEVEL; REVIEW; AGE; ANIMAL; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM DISORDERS; MOUSE; SEX DIFFERENCE;

MUS;

ADIPOKINES; AGE FACTORS; ANIMALS; ATHEROSCLEROSIS; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM DISORDERS; HUMANS; METFORMIN; MICE; SERPINS; SEX FACTORS;

EID: 84928540399     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/823481     Document Type: Review

References (65)

1. K. G. M. M. Alberti, R. H. Eckel, S. M. Grundy et al. , "Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity, " Circulation, vol. 120, no. 16, pp. 1640-1645, 2009.
2. J.-P. Després, A. Cartier, M. Côté, and B. J. Arsenault, "The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology, " Annals of Medicine, vol. 40, no. 7, pp. 514-523, 2008.
3. G. Fruhbeck, J. Gomez-Ambrosi, F. J. Muruzabal, and M. A. Burrell, "The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation, " The American Journal of Physiology-Endocrinology and Metabolism, vol. 280, no. 6, pp. 827-847, 2001.
4. E. E. Kershaw and J. S. Flier, "Adipose tissue as an endocrine organ, " Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2548-2556, 2004.
5. B. L. Wajchenberg, "Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome, " Endocrine Reviews, vol. 21, no. 6, pp. 697-738, 2000.
6. K. Hida, J. Wada, J. Eguchi et al. , "Visceral adipose tissuederived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 30, pp. 10610-10615, 2005.
7. J. Wada, "Vaspin: a novel serpin with insulin-sensitizing effects, " Expert Opinion on Investigational Drugs, vol. 17, no. 3, pp. 327-333, 2008.
8. Q. Li, R. Chen, J. Moriya et al. , "A novel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity, " Journal of International Medical Research, vol. 36, no. 4, pp. 625-629, 2008.
9. P. G. W. Gettins, "Serpin structure, mechanism, and function, " Chemical Reviews, vol. 102, no. 12, pp. 4751-4804, 2002.
10. A. Nakatsuka, J. Wada, I. Iseda et al. , "Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex, " Diabetes, vol. 61, no. 11, pp. 2823-2832, 2012.
11. A. Nakatsuka, J. Wada, I. Iseda et al. , "Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltagedependent anion channel complex, " Circulation Research, vol. 112, no. 5, pp. 771-780, 2013.
12. S. Liu, Y. Dong, T. Wang et al. , "Vaspin inhibited proinflammatory cytokine induced activation of nuclear factor-kappa B and its downstream molecules in human endothelial EA. hy926 cells, " Diabetes Research and Clinical Practice, vol. 103, no. 3, pp. 482-488, 2014.
13. M. Blüher, "Vaspin in obesity and diabetes: pathophysiological and clinical significance, " Endocrine, vol. 41, no. 2, pp. 176-182, 2012.
14. J. T. Heiker, N. Klöting, P. Kovacs et al. , "Vaspin inhibits kallikrein 7 by serpin mechanism, " Cellular and Molecular Life Sciences, vol. 70, no. 14, pp. 2569-2583, 2013.
15. J. T. Heiker, "Vaspin (serpinA12) in obesity, insulin resistance, and inflammation, " Journal of Peptide Science, vol. 20, no. 5, pp. 299-306, 2014.
16. B.-S. Youn, N. Klöting, J. Kratzsch et al. , "Serum vaspin concentrations in human obesity and type 2 diabetes, " Diabetes, vol. 57, no. 2, pp. 372-377, 2008.
17. S. Teshigawara, J. Wada, K. Hida et al. , "Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population, " Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 7, pp. E1202-E1207, 2012.
18. K. Hida, P. Poulsen, S. Teshigawara et al. , "Impact of circulating vaspin levels on metabolic variables in elderly twins, " Diabetologia, vol. 55, no. 2, pp. 530-532, 2012.
19. J. Breitfeld, A. Tönjes, Y. Böttcher et al. , "Genetic variation in the vaspin gene affects circulating serum vaspin concentrations, " International Journal of Obesity, vol. 37, no. 6, pp. 861-866, 2013.
20. E. Jeong, B.-S. Youn, D. W. Kim et al. , "Circadian rhythm of serumvaspin in healthymale volunteers: relation tomeals, " The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 4, pp. 1869-1875, 2010.
21. F. Lago, C. Dieguez, J. Gómez-Reino, and O. Gualillo, "The emerging role of adipokines as mediators of inflammation and immune responses, " Cytokine & Growth Factor Reviews, vol. 18, no. 3-4, pp. 313-325, 2007.
22. N. Klöting, J. Berndt, S. Kralisch et al. , "Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes, " Biochemical and Biophysical Research Communications, vol. 339, no. 1, pp. 430-436, 2006.
23. H. M. Chang, H. J. Lee, H. S. Park et al. , "Effects of weight reduction on serum vaspin concentrations in obese subjects: modification by insulin resistance, " Obesity, vol. 18, no. 11, pp. 2105-2110, 2010.
24. J. N. Fain, B. Buehrer, S. W. Bahouth, D. S. Tichansky, and A. K. Madan, "Comparison of messenger RNA distribution for 60 proteins in fat cells vs the nonfat cells of human omental adipose tissue, "Metabolism: Clinical and Experimental, vol. 57, no. 7, pp. 1005-1015, 2008.
25. C. R. González, J. E. Caminos, M. J. Vázquez et al. , "Regulation of visceral adipose tissue-derived serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue, " Journal of Physiology, vol. 587, no. 14, pp. 3741-3750, 2009.
26. D. S. Edgerton, K. M. S. Johnson, andA. D. Cherrington, "Current strategies for the inhibition of hepatic glucose production in type 2 diabetes, " Frontiers in Bioscience, vol. 14, no. 3, pp. 1169-1181, 2009.
27. N. E. Gulcelik, J. Karakaya, A. Gedik, A. Usman, and A. Gurlek, "Serum vaspin levels in type 2 diabetic women in relation to microvascular complications, " European Journal of Endocrinology, vol. 160, no. 1, pp. 65-70, 2009.
28. B. K. Tan, D. Heutling, J. Chen et al. , "Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance, " Diabetes, vol. 57, no. 6, pp. 1501-1507, 2008.
29. A. Handisurya, M. Riedl, G. Vila et al. , "Serum vaspin concentrations in relation to insulin sensitivity following RYGBinduced weight loss, " Obesity Surgery, vol. 20, no. 2, pp. 198-203, 2010.
30. H. M. Chang, H. S. Park, C.-Y. Park, Y. S. Song, and Y. J. Jang, "Association between serum vaspin concentrations and visceral adipose tissue in Korean subjects, " Metabolism: Clinical and Experimental, vol. 59, no. 9, pp. 1276-1281, 2010.
31. S. Suleymanoglu, E. Tascilar, O. Pirgon, S. Tapan, C. Meral, and A. Abaci, "Vaspin and its correlation with insulin sensitivity indices in obese children, " Diabetes Research and Clinical Practice, vol. 84, no. 3, pp. 325-328, 2009.
32. M. K. Lee, Y. Jekal, J.-A. Im et al. , "Reduced serum vaspin concentrations in obese children following short-termintensive lifestylemodification, " Clinica Chimica Acta, vol. 411, no. 5-6, pp. 381-385, 2010.
33. T. Han, J. Cho, C. Ha, and H. Kang, "Serumvaspin levels and its relation to body fat and fitness, "TheJournal of ExerciseNutrition and Biochemistry, vol. 17, no. 3, pp. 81-86, 2013.
34. S. H. Choi, S. H. Kwak, Y. Lee et al. , "Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women, " Clinical Endocrinology, vol. 75, no. 5, pp. 628-635, 2011.
35. A. Esteghamati, S. Noshad, M. Mousavizadeh, A. Zandieh, and M. Nakhjavani, "Association of vaspin with metabolic syndrome: the pivotal role of insulin resistance, " Diabetes and Metabolism Journal, vol. 38, no. 3, pp. 242-243, 2014.
36. J. M. Kim, T. N. Kim, and J. C. Won, "Association between serum vaspin level and metabolic syndrome in healthy korean 6, pp. 385-391, 2013.
37. T. Yan, L. Li, H. Wang et al. , "Correlation between adipocytokines levels and metabolic syndrome in type 2 diabetes mellitus, " Nan Fang Yi Ke Da Xue Xue Bao, vol. 34, no. 2, pp. 275-278, 2014.
38. J. Seeger, M. Ziegelmeier, A. Bachmann et al. , "Serum levels of the adipokine vaspin in relation to metabolic and renal parameters, " The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 1, pp. 247-251, 2008.
39. B. Karbek, N. C. Bozkurt, O. Topaloglu et al. , "Relationship of vaspin and apelin levels with insulin resistance and atherosclerosis in metabolic syndrome, "Minerva Endocrinologica, vol. 39, no. 2, pp. 99-105, 2014.
40. C. von Loeffelholz, M. Möhlig, A. M. Arafat et al. , "Circulating vaspin is unrelated to insulin sensitivity in a cohort of nondiabetic humans, " European Journal of Endocrinology, vol. 162, no. 3, pp. 507-513, 2010.
41. T. Auguet, Y. Quintero, D. Riesco et al. , "New adipokines vaspin and omentin. Circulating levels and gene expression in adipose tissue frommorbidly obese women, "BMCMedical Genetics, vol. 12, article 60, 2011.
42. J. Bashiri, A. Rahbaran, F. Gholami, S. Ahmadizad, S. Nikoukheslat, and A. Moradi, "The effect of acute exercise on serum vaspin level and its relation to insulin sensitivity in overweight elderly men, " Zahedan Journal of Research in Medical Sciences, vol. 16, no. 8, pp. 10-13, 2013.
43. M. Blüher, A. Rudich, N. Klöting et al. , "Two patterns of adipokine and other biomarker dynamics in a long-termweight loss intervention, " Diabetes Care, vol. 35, no. 2, pp. 342-349, 2012.
44. S. M. Kim, G. J. Cho, M. Yannakoulia et al. , "Lifestyle modification increases circulating adiponectin concentrations but does not change vaspin concentrations, " Metabolism: Clinical and Experimental, vol. 60, no. 9, pp. 1294-1299, 2011.
45. E. Esaki, H. Adachi, Y. Hirai et al. , "Serum vaspin levels are positively associated with carotid atherosclerosis in a general population, " Atherosclerosis, vol. 233, no. 1, pp. 248-252, 2014.
46. A. Thörne, F. Lönnqvist, J. Apelman, G. Hellers, and P. Arner, "A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding, " International Journal of Obesity, vol. 26, no. 2, pp. 93-99, 2002.
47. A. H. Berg, T. P. Combs, and P. E. Scherer, "ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism, " Trends in Endocrinology & Metabolism, vol. 13, no. 2, pp. 84-89, 2002.
48. R. S. Ahima and S. Y. Osei, "Adipokines in obesity, " Frontiers of Hormone Research, vol. 36, pp. 182-197, 2007.
49. G. Fantuzzi and T. Mazzone, "Adipose tissue and atherosclerosis: exploring the connection, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 5, pp. 996-1003, 2007.
50. O. Leal Vde and D. Mafra, "Adipokines in obesity, " Clinica Chimica Acta, vol. 419, pp. 87-94, 2013.
51. M. A. Kobat, A. Celik, M. Balin et al. , "The investigation of serum vaspin level in atherosclerotic coronary artery disease, " Journal of Clinical Medicine Research, vol. 4, no. 2, pp. 110-113, 2012.
52. G. Aust, O. Richter, S. Rohm et al. , "Vaspin serum concentrations in patients with carotid stenosis, " Atherosclerosis, vol. 204, no. 1, pp. 262-266, 2009.
53. H. S. Cura, H. H. Özdemir, C. F. Demir, S. Bulut, N. Ilhan, and M. F. Inci, "Investigation of vaspin level in patients with acute ischemic stroke, " Journal of Stroke and CerebrovascularDiseases, vol. 23, no. 3, pp. 453-456, 2014.
54. N. P. E. Kadoglou, A. Gkontopoulos, A. Kapelouzou et al. , "Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study, " Clinica Chimica Acta, vol. 412, no. 1-2, pp. 48-52, 2011.
55. S. I. Al-Azzam, K. H. Alzoubi, J. A. Abeeleh, N. M. Mhaidat, andM. Abu-Abeeleh, "Effect of statin therapy on vaspin levels in type 2 diabetic patients, " Clinical Pharmacology: Advances and Applications, vol. 5, no. 1, pp. 33-38, 2013.
56. K. Kempf, B. Rose, T. Illig et al. , "Vaspin (SERPINA12) genotypes and risk of type 2 diabetes: results from the MONICA/KORA studies, " Experimental and Clinical Endocrinology & Diabetes, vol. 118, no. 3, pp. 184-189, 2010.
57. Y. Ye, X.-H. Hou, X.-P. Pan, J.-X. Lu, and W.-P. Jia, "Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes, " Chinese Medical Journal, vol. 122, no. 21, pp. 2530-2533, 2009.
58. K. Li, L. Li, M. Yang et al. , "Short-termcontinuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetesmellitus concomitant with improvement in insulin sensitivity, " European Journal of Endocrinology, vol. 164, no. 6, pp. 905-910, 2011.
59. R.-N. Feng, C. Wang, C.-H. Sun, F.-C. Guo, C. Zhao, and Y. Li, "Vaspin in newly and previously diagnosed Chinese type 2 diabetic females: a case-control study, " Asian Biomedicine, vol. 5, no. 4, pp. 525-529, 2011.
60. W. Jian, W. Peng, S. Xiao et al. , "Role of serum vaspin in progression of type 2 diabetes: a 2-year cohort study, " PLoS ONE, vol. 9, no. 4, Article ID e94763, 2014.
61. H. B. Atya, Z. A. Hassan, A. I. Amin, and S. A. E. Ali, "Vaspin concentration in obesity, impaired glucose tolerance and type 2 diabetes in Egypt, " Advanced Research in Biological Sciences, vol. 1, no. 1, pp. 6-13, 2013.
62. H. O. El-Mesallamy, D. H. Kassem, E. El-Demerdash, and A. I. Amin, "Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus, " Metabolism: Clinical and Experimental, vol. 60, no. 1, pp. 63-70, 2011.
63. Z. Li, C. Ma, L. Li, X. Pan, and L. Chen, "Vaspin serum concentration in patients with type 2 diabetes and carotid plaque, " The Journal of International Medical Research, vol. 40, no. 5, pp. 1670-1676, 2012.
64. R. N. Feng, Y. Li, C. Wang et al. , "Higher vaspin levels in subjects with obesity and type 2 diabetes mellitus: a meta-analysis, " Diabetes Research and Clinical Practice, vol. 106, no. 1, pp. 88-94, 2014.
65. M. Blüher, "Adipokines-removing road blocks to obesity and diabetes therapy, " Molecular Metabolism, vol. 3, no. 3, pp. 230-240, 2014.